

CELLULAR THERAPY

Day 0

PRE-INFUSION

Cell collection procedure - Apheresis:

Date of collection: ____/____/____ (YYYY/MM/DD)
(If more than one collection enter the date of the first collection.)

Date unknown
(e.g. allogeneic product
from unknown donor)

Number of collections: _____

Was the first collection used for production? No Yes

If first collection was not used for production:

Was a second, unplanned collection performed? No Yes

Was the second collection used for production?

No

Yes: **Date of collection:** ____/____/____ (YYYY/MM/DD)

Type of cellular therapy? *(Please do not report cell infusion (e.g. DLI) here. Cell infusion should be reported in cell infusion sheet a section found in the Follow up forms.)*

- CAR-NK cells
- CAR-T cells
- CAR-CIK cells
- TIL therapy
- Other cellular therapy, please specify: _____

INDICATION FOR PLANNED CELLULAR THERAPY

Treatment of a primary disease:

Indication diagnosis for this cellular therapy: _____
(make sure the indication diagnosis has been registered first, using the relevant diagnosis form)

Reason for cellular therapy: (select all that apply)

- Induction therapy
- Prevention of disease relapse or progression
- Rescue from disease relapse or progression
- Minimal residual disease reduction
- Refractory disease
- Other; specify: _____

Other indication; specify: _____

BASIC INFORMATION ON THE PLANNED CELLULAR THERAPY

Clinical setting:
(check only one)

<input type="checkbox"/> As per marketing approval / Standard of care / Institutional guidelines	
<input type="checkbox"/> Hospital exemption	
<input type="checkbox"/> Compassionate use / Accelerated access	
<input type="checkbox"/> Investigational drug product (IDP)/ Clinical trial	Phase: <input type="checkbox"/> 1 <input type="checkbox"/> 1/2 <input type="checkbox"/> 2 <input type="checkbox"/> 2/3 <input type="checkbox"/> 3 Blind trial: <input type="checkbox"/> No <input type="checkbox"/> Yes Randomised trial: <input type="checkbox"/> No <input type="checkbox"/> Yes EudraCT number: _____ USA NCT number: _____ UMIN CT number: _____

Cell origin:

<input type="checkbox"/> Autologous <i>(Proceed to 'Planned cellular therapy infusion product(s)' section on page 4)</i>
<input type="checkbox"/> Allogeneic: <u>This product is manufactured from:</u> <input type="checkbox"/> A known donor never used to treat this patient <i>(e.g. from a donor registry or related)</i> <i>(Proceed to 'Donor information' section on page 3.)</i> <input type="checkbox"/> A donor that is already registered as part of a previous treatment <i>(Proceed to 'Planned cellular therapy infusion product(s)' section on page 4.)</i> <input type="checkbox"/> An unknown donor with no data available <i>(e.g. from a commercial product)</i> <i>(Proceed to 'Planned cellular therapy infusion product(s)' section on page 4)</i>



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

DONOR INFORMATION

Complete only if cell source was allogeneic

Did the donor consent to having their data in the EBMT registry?

No (complete only fields marked with "*" in this section)

Yes

(Skip if the source of stem cells is cord blood)

Date of birth: ____/____/____ (YYYY/MM/DD)

OR:

***Age at time of donation:** _____ years

If the donor was younger than 2 years:

***Age in months:** _____

***Sex (at birth):**

Male

Female

Donor Identification:

Donor ID given by the treating centre (*mandatory*): _____

Global registration identifier for donors (GRID): _____

ION code of the Donor Registry or Cord Blood Bank (*mandatory*): _____

EuroCord code for the Cord Blood Bank (*if applicable*): _____

Name of Donor Registry or Cord Blood Bank: _____

Donor ID given by the Donor Registry or Cord Blood Bank: _____

Patient ID given by the Donor Registry or Cord Blood Bank: _____



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

PLANNED CELLULAR INFUSION PRODUCT(S)

Will the planned cellular infusion product consist of more than one infusion unit?

- No
- Yes: **Number of infusion units:** _____
- Unknown

Tissue source (check all that apply):

- Bone marrow
- Peripheral blood
- Cord blood
- Tumour
- Other; specify: _____

Is the planned cell infusion product a commercial product?

- No
- Yes

Identification:

Name of manufacturer:

- Autolus
- Celgene/ Bristol-Myers Squibb
- Celyad
- GlaxoSmithKline (GSK)
- Johnson & Johnson
- Kite Gilead
- Miltenyi
- Novartis
- Local hospital or university
- Other; specify: _____

Name of product:

- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Tecartus
- Yescarta
- No product name available
- Other; specify: _____

END OF PRE-INFUSION SECTION

PLEASE PROCEED WITH THE CELLULAR THERAPY SECTION TO COMPLETE
THE CELLULAR THERAPY DAY 0 REPORT

CELLULAR THERAPY

Date of (planned) cell infusion: ____/____/____ (YYYY/MM/DD)

Centre where infusion took place (CIC): _____

(if the product was not infused, report the centre where the infusion was planned to take place)

Patient UPN for this treatment: _____

Team or unit where treatment took place *(select all that apply)*: Adults Pediatrics Haematology Oncology Allograft Autograft Other; specify: _____Unit number: _____ Not applicable**Was the cellular therapy product infused during this treatment/procedure?**

- No: Reason why the treatment did not take place: *Select all reasons that apply*
- Production failure
 - Out of specification product rejected by physician
 - Disease progression or patient condition worsening
 - Patient became ineligible for treatment
 - Patient died
 - Other reason; specify: _____

- Yes:
- Absolute B-cell count:** _____ $\times 10^9/L$ $\times 10^6/L$ (cells/ μL) Not evaluated Unknown
- Absolute total immune cell count:** _____ $\times 10^9/L$ $\times 10^6/L$ (cells/ μL) Not evaluated Unknown

THERAPY & CELL INFUSION(S)**Chronological number of cellular therapy treatment for this patient:** _____*(Please do not include any transplants or DLIs the patient had in the past)**Complete this section only if this is the second or a subsequent cellular therapy for this patient and the previous cellular treatments cannot be registered.***If > 1:****Same product as for the previous cellular therapy?** No Yes**Date of the last cellular therapy before this one:** ____/____/____ (YYYY/MM/DD)**Type of the last cellular therapy before this one:** Autologous Allogeneic: Was the same donor used both for prior and current cellular therapy? No Yes**Was the last cellular therapy performed at another institution?** No Yes: CIC (if known): _____

Name of institution: _____

City: _____

*If > 1 submit an annual follow-up form before proceeding using the latest assessment date before this cellular therapy; this is so relapse data and other events between transplants/cellular therapies can be captured.***Did the patient receive a previous HCT?** No Yes: **Date of the last HCT before this CT:** ____/____/____ (YYYY/MM/DD)**Type of the last HCT before this CT:** Autologous Allogeneic**For same indication as the cellular therapy?** No Yes



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

PREVIOUS THERAPIES incl. BRIDGING
(before transplant/cellular therapy)

Was the patient treated before this cellular therapy procedure (not including HCT/CT/GT/IST)?

No (*proceed to 'Cellular therapy infusion unit(s)' on page 8*)

Yes

**complete the "Treatment — non-HCT/CT/GT/IST" form before continuing with
'Cellular therapy infusion unit(s)' on page 8)**

Unknown (*proceed to 'Cellular therapy infusion unit(s)' on page 8*)



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

CELLULAR THERAPY INFUSION UNIT(S)

Was there more than one cell infusion unit administered during this treatment?

- No
- Yes: Number of different cell infusion units that were part of this treatment: _____

**CELLULAR THERAPY INFUSION UNIT(S)
DESCRIPTION**

If the CT product was not infused proceed to 'Survival status' section on page 14.

If more than one cell infusion unit please copy and fill-in this section for each one of them.

Unique ID of the product: _____

(If applicable)

Batch number: _____

(If applicable)

Identification of the cell infusion unit given by the centre: _____

(If there is only one cell infusion unit enter "1")

Was the infused cellular product consistent with the specifications?

- No: specify the difference from specifications: _____
- Yes
- Unknown

Was the cellular therapy product cryopreserved prior to infusion?

- No
- Yes
- Unknown



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

CELLULAR THERAPY INFUSION UNIT(S) MANIPULATION

Complete only for non-commercial products. If more than one cell infusion unit please copy and fill-in this section for each one of them.

Identification of the cell infusion unit (given by the centre): _____

Manipulation:

Processing/Manufacturing facility:

- Onsite, by local cell processing facility
- Offsite, by a non-commercial facility

Gene manipulation:

No

Yes: Type

No

Gene transfer:

Yes: Vector: Retroviral vector

Lentiviral vector

Other vector; specify: _____

Transgene: CAR; specify all targets: _____

TCR; specify all targets: _____

specify HLA element: _____

Suicide gene; specify: _____

Other: specify: _____

See appendix 1 for a list of target antigens

Other: No

Yes: specify: _____

**CELLULAR THERAPY INFUSION UNIT(S)
MANIPULATION** continued

Complete only for non-commercial products. If more than one cell infusion unit please copy and fill-in this section for each one of them.

Manipulation aims:**Recognition of a specific target/antigen:**

- No
- Yes: Type (check all that apply):
- | | |
|---|---|
| <input type="checkbox"/> Viral: | <input type="checkbox"/> Fungal: |
| <input type="checkbox"/> Adenovirus | <input type="checkbox"/> Candida |
| <input type="checkbox"/> BK Virus | <input type="checkbox"/> Aspergillus |
| <input type="checkbox"/> Covid-19 (SARS-CoV-2) | <input type="checkbox"/> Other fungus; specify: _____ |
| <input type="checkbox"/> Cytomegalovirus (CMV) | |
| <input type="checkbox"/> Epstein-Barr virus | |
| <input type="checkbox"/> Human herpes virus 6 | |
| <input type="checkbox"/> Human immunodeficiency virus (HIV) | |
| <input type="checkbox"/> RSV-CTL | |
| <input type="checkbox"/> Other virus; specify: _____ | |
- Tumour/cancer antigen(s); specify all: _____
- Other target; specify: _____

Cell types administered (check all that apply):

- CD3+ lymphocytes
- CD4+ lymphocytes
- CD8+ lymphocytes
- CD34+
- Dendritic cells
- Gamma-Delta cells
- Mesenchymal cells
- NK cells
- Regulatory T-cells
- Other; specify: _____

Expansion:

- No
- Yes
- Unknown

Activation:

- No
- Yes
- Unknown

Induced differentiation:

- No
- Yes
- Unknown



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

PREPARATIVE REGIMEN

Do not include lines of therapy given for disease treatment, bridging therapy or maintenance, these should be reported in other form.

Preparative conditioning / lymphodepletion regimen given?

- No
- Yes: **Drugs given?** *(any active agent, including chemotherapy, monoclonal antibody, polyclonal antibody, serotherapy, etc.)*
 - No
 - Yes (provide details in the table on pages 12-13)
 - Unknown

Were any prophylactic (preventive) drugs given for CRS/ICANS?

- No
- Yes: **Drugs given?** *(select all that apply)*
 - Corticosteroids
 - Anakinra
 - Tocilizumab
 - Other prophylactic drug, specify: _____
- Unknown

PREPARATIVE REGIMEN continued

Specification and dose of the preparative regimen:

(Report the total prescribed cumulative dose as per protocol. Multiply daily dose in mg/kg or mg/m² by the number of days; e.g. for Busulfan given 4mg/kg daily for 4days, total dose to report is 16mg/kg.

Report dosages and units only for individual drugs.)

Chemotherapy
Dose
Units

<input type="checkbox"/> Alemtuzumab		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Anti-Thymocyte Globulin Anti-Lymphocyte Globulin Product name: _____ Origin: <input type="checkbox"/> Rabbit <input type="checkbox"/> Horse <input type="checkbox"/> Other; specify: _____		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Bendamustine		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Bleomycin		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Busulfan Route of administration: <input type="checkbox"/> Oral <input type="checkbox"/> IV <input type="checkbox"/> Both Drug monitoring performed: <input type="checkbox"/> No <input type="checkbox"/> Yes; total AUC: _____ <input type="checkbox"/> mg x hr/L <input type="checkbox"/> micromol x min/L <input type="checkbox"/> mg x min/mL		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Carboplatin Drug monitoring performed: <input type="checkbox"/> No <input type="checkbox"/> Yes; total AUC: _____ <input type="checkbox"/> mg x hr/L <input type="checkbox"/> micromol x min/L <input type="checkbox"/> mg x min/mL		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Carmustine		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Cisplatin		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Clofarabine		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
Corticosteroids: <input type="checkbox"/> Beclometasone <input type="checkbox"/> Budesonide <input type="checkbox"/> Dexamethasone <input type="checkbox"/> Methylprednisolone <input type="checkbox"/> Prednisolone		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg <input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Cyclophosphamide		<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg

PREPARATIVE REGIMEN continued

Specification and dose of the preparative regimen:

(Report the total prescribed cumulative dose as per protocol. Multiply daily dose in mg/kg or mg/m² by the number of days; e.g. for Busulfan given 4mg/kg daily for 4days, total dose to report is 16mg/kg.)

Chemotherapy	Dose	Unit
<input type="checkbox"/> Cytarabine	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Daunorubicin	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Doxorubicin	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Epirubicin	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Etoposide	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Fludarabine	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Gemtuzumab ozogamicin	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Ibritumomab tiuxetan	_____	<input type="checkbox"/> mCi <input type="checkbox"/> MBq
<input type="checkbox"/> Idarubicin	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Ifosfamide	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Imatinib	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Lomustine	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Melphalan	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Mitoxantrone	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Paclitaxel	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Anti-CD20 antibodies	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Teniposide	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Thiotepa	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Tositumomab	_____	<input type="checkbox"/> mCi <input type="checkbox"/> MBq
<input type="checkbox"/> Treosulfan	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg
<input type="checkbox"/> Other; specify*: _____	_____	<input type="checkbox"/> mg/m ² <input type="checkbox"/> mg/kg <input type="checkbox"/> mCi <input type="checkbox"/> MBq

*Please consult the **LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS** on the EBMT website for drugs/regimens names

Has the chemotherapy dose been adjusted according organ dysfunction and/or body weight?

<input type="checkbox"/> No	
<input type="checkbox"/> Yes, reason for dose adjustment (select all that apply):	<input type="checkbox"/> Renal impairment <input type="checkbox"/> Hepatic impairment <input type="checkbox"/> Overweight/obesity <input type="checkbox"/> Underweight <input type="checkbox"/> Other reason for adjustment, specify: _____
<input type="checkbox"/> Unknown	

Total body irradiation (TBI):

No

Yes; **total prescribed radiation dose as per protocol (Gy):** _____

number of fractions: _____

number of radiation days: _____



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

CELL INFUSION EPISODE(S)

Was there more than one cell infusion episodes during this treatment or procedure?

- No
- Yes: Number of cell infusion episodes during this treatment/procedure: _____

CELL INFUSION EPISODE(S) DESCRIPTION

If more than one cell infusion unit please copy and fill-in this section for each one of them.

Date of cell infusion episode: ____/____/____ (YYYY/MM/DD)

Route of infusion:
(check all that apply)

- Intravenous
- Intrathecal
- Intratumour injection
- Other route; specify: _____

Did the patient receive concomitant therapy?

- No
- Yes; specify: _____

Treatment given: Simultaneously to the cellular therapy
 After the cellular therapy episode was finished

If more than one unit was used, indicate the identification of the cell infusion given by the centre as described in the 'Cell Infusion Unit' section (This item is mandatory if more than one cell infusion unit was used.): _____

Is the exact number of cells infused available?

- No
- Yes: Number of cells: _____ Unit (check only one): 10⁶/kg 10⁶ 10⁸/kg 10⁸
(not adjusted for cell viability)

Cell viability %: _____

If more than one cell infusion unit was administered please copy and fill-in this section for each one of them.

END OF THE CELLULAR THERAPY DAY 0 REPORT
proceed to form DISEASE STATUS AT HCT/CT/GT/IST



EBMT Centre Identification Code (CIC): _____

Treatment Date ____/____/____ (YYYY/MM/DD)

Hospital Unique Patient Number (UPN): _____

Embargo end date ____/____/____ (YYYY/MM/DD)

Patient Number in EBMT Registry: _____

Appendix 1
-- List of transgene CAR targets --

- AFP (alpha fetoprotein)
- BAFF-R
- BCMA
- B7H3
- CD11
- CD16
- CD19
- CD20
- CD22
- CD30
- CD33
- CD38
- CD56
- CD123
- CD138
- CD171
- CD229
- CLL1
- CS-1 (SLAMF7)
- EGFR
- GD2
- GPRC5D
- HER2
- HPV-16E6
- Integrin β 7
- Lewis-Y
- MAGE-A4
- MAGE-A10
- Mesothelin (MSLN)
- MUC16
- NKG2D
- NY-ESO-1
- PRAME
- PSCA
- SSX
- Survivin
- TACI
- WT-1
- Other (specify)